机构:[1]Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center,School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院四川省肿瘤医院[2]Department ofRadiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University ofElectronic Science and Technology of China, Chengdu, China四川省肿瘤医院[3]Department of Thoracic Surgery, Sichuan Cancer Hospitaland Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China,Chengdu, China外科中心胸外科中心四川省人民医院四川省肿瘤医院胸外科
Background This study aimed to establish an effective and practical prognostic index for esophageal squamous cell cancer (ESCC) based on the coagulation factors. Methods The training cohort of 965 patients with ESCC was retrospectively collected at Sichuan Cancer Hospital from 2012 to 2014, along with clinical characteristics and follow-up information. Risk factors of coagulation status, including 11 blood parameters (platelet [PLT], mean platelet volume [MPV], platelet distribution width [PDW], plateletocrit [PCT], thrombin time [TT], prothrombin time [PT], international normalized ratio [INR], activated partial thromboplastin time [APTT], fibrinogen, D-dimer, and fibrinogen degradation product [FDP]), were studied by least absolute shrinkage and selection operator (LASSO) Cox regression and the Coagulation Index was established. The index was validated in a cohort of 848 patients with ESCC at the same institution, from 2015 to 2016. Results Three variables of PLT, MPV, and fibrinogen were identified by selecting features with coefficients in the LASSO algorithm, and a Coagulation Index was established as follows: Coagulation Index = 0.0005 x PLT (10(9)/L) - 0.0384 x MPV (fL) + 0.1148 x fibrinogen (g/L). A higher Coagulation Index score was significantly associated with higher pT stage and pN stage (p < 0.05). With this prognostic index, patients could be stratified into three risk groups. The 3-year overall survival (OS) rates of the low-, middle- and high-risk groups in the training cohort were 63.5%, 55.5% and 43.1%, respectively (log-rank p < 0.001). Similarly, in the validation set, the respective 3-year OS for each risk group was significantly different across the three risk groups. Multivariate analysis indicated that the Coagulation Index remained a significant factor for predicting OS, independently of pathological TNM stage. Conclusions The Coagulation Index is an independent predictor of survival for patients with ESCC.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81872402]; Sichuan Science and Technology Department Key Research and Development Project Fund [2019YFS0378, 2018JY0277]; Wu Jieping Medical Foundation [320.6750.17237, 2017YFC0113100]
第一作者机构:[1]Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center,School of Medicine, University of Electronic Science and Technology of China, Chengdu, China[2]Department ofRadiation Oncology, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, School of Medicine, University ofElectronic Science and Technology of China, Chengdu, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Wang Qifeng,Cao Bangrong,Peng Lin,et al.Development and Validation of a Practical Prognostic Coagulation Index for Patients with Esophageal Squamous Cell Cancer[J].ANNALS OF SURGICAL ONCOLOGY.2021,28(13):8450-8461.doi:10.1245/s10434-021-10239-z.
APA:
Wang, Qifeng,Cao, Bangrong,Peng, Lin,Dai, Wei,Jiang, Yinchun...&Mi, Kun.(2021).Development and Validation of a Practical Prognostic Coagulation Index for Patients with Esophageal Squamous Cell Cancer.ANNALS OF SURGICAL ONCOLOGY,28,(13)
MLA:
Wang, Qifeng,et al."Development and Validation of a Practical Prognostic Coagulation Index for Patients with Esophageal Squamous Cell Cancer".ANNALS OF SURGICAL ONCOLOGY 28..13(2021):8450-8461